ES2180702T3 - Tratamiento de patologias por la induccion del factor de transcripcion bef-1. - Google Patents

Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Info

Publication number
ES2180702T3
ES2180702T3 ES96303876T ES96303876T ES2180702T3 ES 2180702 T3 ES2180702 T3 ES 2180702T3 ES 96303876 T ES96303876 T ES 96303876T ES 96303876 T ES96303876 T ES 96303876T ES 2180702 T3 ES2180702 T3 ES 2180702T3
Authority
ES
Spain
Prior art keywords
bef
transcription factor
pathologies
induction
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96303876T
Other languages
English (en)
Inventor
David Thompson Berg
David Scott Calnek
Brian William Grinnell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2180702T3 publication Critical patent/ES2180702T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

UN METODO PARA INDUCIR EL FACTOR DE TRANSCRIPCION BEF-1 QUE CONSISTE EN ADMINISTRAR A UNA PERSONA QUE LO NECESITE UNA CANTIDAD EFICAZ DE UN COMPUESTO CON LA FORMULA DONDE R{SUP,1} Y R{SUP,3} SON, INDEPENDIENTEMENTE, HIDROGENO, CH{SUB,3}, -C=O-(C{SUB,1}-C{SUB,6} ALQUIL) O -C=O-AR, DONDE AR ES UN FENILO OPCIONALMENTE SUSTITUIDO; R{SUP,2} SE SELECCIONA DE UN GRUPO FORMADO POR PIRROLIDINA, HEXAMETILENAMINO Y PIPERIDINO O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE ESTOS COMPUESTOS SOLVATADOS.
ES96303876T 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1. Expired - Lifetime ES2180702T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47949895A 1995-06-07 1995-06-07

Publications (1)

Publication Number Publication Date
ES2180702T3 true ES2180702T3 (es) 2003-02-16

Family

ID=23904277

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96303876T Expired - Lifetime ES2180702T3 (es) 1995-06-07 1996-05-30 Tratamiento de patologias por la induccion del factor de transcripcion bef-1.

Country Status (8)

Country Link
EP (1) EP0747051B1 (es)
JP (1) JPH11506771A (es)
AU (1) AU6040296A (es)
BR (1) BR9609053A (es)
CA (1) CA2223175A1 (es)
DE (1) DE69622472T2 (es)
ES (1) ES2180702T3 (es)
WO (1) WO1996040130A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
KR101629356B1 (ko) 2008-06-26 2016-06-13 리스버로직스 코퍼레이션 퀴나졸리논 유도체의 제조방법
CA2747417C (en) 2009-01-08 2017-01-03 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
DK2421533T3 (en) 2009-04-22 2019-01-07 Resverlogix Corp Hitherto unknown anti-inflammatory agents
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
EP0963756B1 (en) * 1993-12-21 2004-02-25 Eli Lilly And Company Inhibition of advanced glycosylation end products
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US5492927A (en) * 1993-12-21 1996-02-20 Eli Lilly And Company Non-peptide tachykinin receptor antagonists to treat allergy
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin

Also Published As

Publication number Publication date
CA2223175A1 (en) 1996-12-19
WO1996040130A1 (en) 1996-12-19
BR9609053A (pt) 1999-01-26
AU6040296A (en) 1996-12-30
EP0747051A3 (en) 1997-02-26
EP0747051B1 (en) 2002-07-24
JPH11506771A (ja) 1999-06-15
DE69622472D1 (de) 2002-08-29
DE69622472T2 (de) 2003-02-06
EP0747051A2 (en) 1996-12-11

Similar Documents

Publication Publication Date Title
ES2180702T3 (es) Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
ES2184850T3 (es) Peptidos y analogos peptidicos como inhibidores de proteasa.
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
ES2153851T3 (es) Tratamiento de la atrofia de la piel y de la vagina.
ES2102154T3 (es) Inhibicion de trombina.
DE69329386D1 (de) Substituierte benzylaminoquinuclidine als substanz p antagonisten
FI943542A0 (fi) Trisyklisiä bentsatsepiineja, jotka ovat vasopressiiniantagonisteja
ES2175336T3 (es) Derivados de triazol utiles en terapia.
EA200801806A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
NO20044458L (no) Anvendelse av en ringsystemforbindelse for fremstilling av et medikament
ES2122456T3 (es) Aminoacidos excitadores sinteticos.
UY24935A1 (es) Antagonistas del receptor de vitronectina
ATE25682T1 (de) Indol-3-carboxamid-derivate.
DE69415507D1 (de) Analoge von acylfulven als antitumormittel
KR910016915A (ko) 과콜레스테롤혈증 치료제
ATE220904T1 (de) 2-phenyl-3-azoylbenzothiophene zur erhöhung der thrombomodulin expression
RU99107566A (ru) Производные, обладающие противосудорожным действием, пригодные для лечения невропатической боли
SE9400810D0 (sv) New use of Quinoline-3-carboxamide compounds
ES2104509A1 (es) Nuevos compuestos derivados de 2-(3,4-disustituido-1-piperazinil)-5-fluoropirimidina.
ES2178382T3 (es) Compuestos de benciloxiprodigiosina.
ES2170804T3 (es) Derivados de dihidro-2,3-benzodiazepina.
ATE140693T1 (de) Phenylalkylaminoalkyl-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK0404055T3 (da) Antimetastatisk virksomt stof fra den sydamerikanske igle Haementeria ghilianii
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.